A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).

PALBOCICLIB VERSUS CAPECITABINA EM ESTUDO PEARL PHASE 2 EM PACIENTES PRÉ MENOPAUSADAS, HER-2 NEGATIVOS LUMINAIS PFS 20,1 X 14,4 MESES